Literature DB >> 19483705

Chronic myelogenous leukaemia market.

Shane Storey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19483705     DOI： 10.1038/nrd2873

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  8 in total

1.  NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

Authors:  Susan O'Brien; Ellin Berman; Hossein Borghaei; Daniel J Deangelo; Marcel P Devetten; Steven Devine; Harry P Erba; Jason Gotlib; Madan Jagasia; Joseph O Moore; Tariq Mughal; Javier Pinilla-Ibarz; Jerald P Radich; Neil P Shah Md; Paul J Shami; B Douglas Smith; David S Snyder; Martin S Tallman; Moshe Talpaz; Meir Wetzler
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

2.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Authors:  Hagop Kantarjian; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

3.  Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

Authors:  Moshe Talpaz; Richard T Silver; Brian J Druker; John M Goldman; Carlo Gambacorti-Passerini; Francois Guilhot; Charles A Schiffer; Thomas Fischer; Michael W N Deininger; Anne L Lennard; Andreas Hochhaus; Oliver G Ottmann; Alois Gratwohl; Michele Baccarani; Richard Stone; Sante Tura; Francois-Xavier Mahon; Sofia Fernandes-Reese; Insa Gathmann; Renaud Capdeville; Hagop M Kantarjian; Charles L Sawyers
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

4.  Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.

Authors:  Jorge Cortes; Elias Jabbour; Hagop Kantarjian; C Cameron Yin; Jianqin Shan; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Megan Breeden; Nubia Reeves; William G Wierda; Dan Jones
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

5.  Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  IDrugs       Date:  2008-05

6.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Stephen G O'Brien; François Guilhot; Richard A Larson; Insa Gathmann; Michele Baccarani; Francisco Cervantes; Jan J Cornelissen; Thomas Fischer; Andreas Hochhaus; Timothy Hughes; Klaus Lechner; Johan L Nielsen; Philippe Rousselot; Josy Reiffers; Giuseppe Saglio; John Shepherd; Bengt Simonsson; Alois Gratwohl; John M Goldman; Hagop Kantarjian; Kerry Taylor; Gregor Verhoef; Ann E Bolton; Renaud Capdeville; Brian J Druker
Journal:  N Engl J Med       Date:  2003-03-13       Impact factor: 91.245

7.  Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.

Authors:  Andreas Hochhaus; Brian Druker; Charles Sawyers; Francois Guilhot; Charles A Schiffer; Jorge Cortes; Dietger W Niederwieser; Carlo Gambacorti-Passerini; Carlo Gambacorti; Richard M Stone; John Goldman; Thomas Fischer; Stephen G O'Brien; Jose J Reiffers; Manisha Mone; Tillmann Krahnke; Moshe Talpaz; Hagop M Kantarjian
Journal:  Blood       Date:  2007-10-11       Impact factor: 22.113

8.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Authors:  Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil Bhalla; Giuliana Alimena; Francesca Palandri; Gert J Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra J Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Journal:  Blood       Date:  2007-08-22       Impact factor: 22.113
  8 in total
  5 in total

1.  Targeted cancer therapies.

Authors:  Saurabh Aggarwal
Journal:  Nat Rev Drug Discov       Date:  2010-06       Impact factor: 84.694

2.  The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Authors:  V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann
Journal:  Leukemia       Date:  2015-03-18       Impact factor: 11.528

3.  Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.

Authors:  Michael Lauseker; Roman Gerlach; Martin Tauscher; Joerg Hasford
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-16       Impact factor: 4.553

4.  A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.

Authors:  Tzu-Yi Yang; Christie L Eissler; Mark C Hall; Laurie L Parker
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

5.  The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective.

Authors:  Ying Hong Li; Pan Pan Wang; Xiao Xu Li; Chun Yan Yu; Hong Yang; Jin Zhou; Wei Wei Xue; Jun Tan; Feng Zhu
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.